Chemomab Therapeutics (CMMB) Cash & Current Investments (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Cash & Current Investments data on file, last reported at $10.4 million in Q4 2025.

• Quarterly Cash & Current Investments fell 27.34% year-over-year to $10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (down 27.34% YoY) and the FY2025 annual result came in at $10.4 million, down 27.34% from the prior year.
• Cash & Current Investments grew to $10.4 million in Q4 2025, from $10.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $66.9 million in Q2 2021 to a low of $9.5 million in Q2 2025.
• A 5-year average of $32.5 million and a median of $24.1 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments surged 849.59% — and 2023, when it tumbled 53.93%.
• Tracing CMMB's Cash & Current Investments over 5 years: stood at $61.2 million in 2021, then tumbled by 34.77% to $39.9 million in 2022, then sank by 50.41% to $19.8 million in 2023, then declined by 27.89% to $14.3 million in 2024, then slipped by 27.34% to $10.4 million in 2025.
• The last three Cash & Current Investments figures came in at $10.4 million (Q4 2025), $10.1 million (Q3 2025), and $9.5 million (Q2 2025), per Business Quant data.